Premium
Impact of genotypic susceptibility score on cART outcomes during primary HIV infection
Author(s) -
Giacomelli Andrea,
Fabbiani Massimiliano,
Benedetto Ilaria,
Nozza Silvia,
Focà Emanuele,
Celesia Benedetto M.,
Marchetti Giulia,
Mussini Cristina,
Antinori Andrea,
d’Ettorre Gabriella,
Madeddu Giordano,
Bandera Alessandra,
Muscatello Antonio,
Rusconi Stefano
Publication year - 2019
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.25517
Subject(s) - cart , confidence interval , regimen , medicine , odds ratio , human immunodeficiency virus (hiv) , clinical endpoint , antiretroviral therapy , genotype , virology , viral load , randomized controlled trial , biology , mechanical engineering , biochemistry , engineering , gene
Abstract To assess the impact of genotypic susceptibility score (GSS) on combined antiretroviral therapy (cART) outcomes during primary HIV infection (PHI) we retrospectively enrolled patients with PHI diagnosed between 2008 and 2015 at 9/24 Italian Network ACuTe HIV InfectiON centers. One hundred‐seventy‐six patients were enrolled. Of these, 55 (32.9%) patients started with more than three drugs and 11 (7.2%) started with a GSS < 3. Regimen's GSS (per 1 point increase) (adjusted odds ratio [aOR], 4.82; 95% confidence interval [CI], 1.62‐14.28; P = .005) and baseline HIV‐RNA (per 1 log10 increase) (aOR, 2.02; 95% CI, 1.09‐3.73; P = .025) resulted associated with early cART initiation. In conclusion, regimen's GSS resulted to be associated to the time to cART initiation during PHI.